Table 15.
construct | Epitope sequence (HPV-Type) | Antigenicity* | Molecular weight (Da) | Instability index of constructs | Solubility index of constructs** | In vivo half time |
---|---|---|---|---|---|---|
L1 | EATVYLPPVPVSKVVA (16) | 0.5397 | 28227 | 47.52(stable) | 0.648(soluble) | >20 hours |
DNTVYLPPPSVARV (18) | 0.2280 | |||||
DTYRFVTSQAIACQK (16) | 0.1995 | |||||
DTYRFVQSVAITCQK (18) | 0.3133 | |||||
YLPPVPVSKV (16) | 1.0876 | |||||
YLPPPSVARV (18) | 0.4104 | |||||
DQFPLGRKFLL (16) | 0.2797 | |||||
DQYPLGRKFLV (18) | 0.6476 | |||||
L2 | PDFLDIVALHRPALTSR (16) | 1.1115 | 25674 | 34.01(Stable) | 0.407(soluble) | >20 hours |
SDFMDIIRLHRPALTSR (18) | 0.4570 | |||||
FFGGLGIGTGSGTGGR (16) | 1.0724 | |||||
DPSIVTLIEDSSVVTSGAP (18) | 0.4474 | |||||
KRASATQLYK (16) | 0.1484 | |||||
KRASVTDLYK (18) | 0.4778 | |||||
DPDFLDIVALHR (16) | 1.6210 | |||||
DSDFMDIIRLHR (18) | 0.3371 |
*higher rate shows high degree of peptide antigenicity.
**higher rate shows high degree of peptide solubility.